Suppr超能文献

作为冠状病毒病治疗药物的伊维菌素的使用知识、态度及流行情况:一项针对马来西亚人群的横断面研究。

Knowledge, attitude and prevalence of ivermectin use as coronavirus disease treatment: A crosssectional study among a Malaysian population.

作者信息

Filza Nur Athirah Tar'ali, Aina Amanina Abdul Jalil, Nor Safwan Hadi Nor Afendi

机构信息

BPharm, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia.

BPharm, MClin Pharm, Faculty of Pharmacy and Health Sciences, Royal College of Medicine Perak, Universiti Kuala Lumpur, Ipoh, Perak, Malaysia. Email:

出版信息

Malays Fam Physician. 2024 Jan 6;19:2. doi: 10.51866/oa.415. eCollection 2024.

Abstract

INTRODUCTION

During the coronavirus disease (COVID-19) pandemic, there was a widespread public misconception regarding ivermectin use in managing the disease. There is no approval of ivermectin as COVID-19 treatment by the Food and Drug Administration, and the adverse effects of the drug are alarming. This study aimed to evaluate the knowledge and attitude towards and prevalence of ivermectin use as COVID-19 treatment among the Malaysian population.

METHODS

This cross-sectional study was conducted among 391 Malaysians aged ≥18 years. A validated online self-administered questionnaire disseminated via Google Forms was used to evaluate the knowledge and attitude towards and prevalence of ivermectin use as COVID-19 treatment. The socio-demographic characteristics and knowledge and attitude towards and prevalence of ivermectin use among the respondents were evaluated through descriptive analysis. The chi-square test was used to identify the association between the variables.

RESULTS

The respondents had moderate levels of knowledge and attitude towards ivermectin use, while the prevalence of ivermectin use was 3.58%. The respondents' sex (P=0.014), age (P=0.012) and monthly income (P=0.049) were significantly associated with their level of knowledge. The respondents' sex (P=0.04) was significantly associated with their level of attitude. Conversely, no socio-demographic characteristics were significantly associated with the prevalence of ivermectin use as COVID-19 treatment.

CONCLUSION

The majority of Malaysians have moderate levels of knowledge and attitude towards ivermectin use as COVID-19 treatment, with a low prevalence of actual use.

摘要

引言

在冠状病毒病(COVID-19)大流行期间,公众对使用伊维菌素治疗该疾病存在广泛的误解。美国食品药品监督管理局未批准将伊维菌素用于治疗COVID-19,且该药物的不良反应令人担忧。本研究旨在评估马来西亚人群对使用伊维菌素治疗COVID-19的知识、态度及使用情况。

方法

本横断面研究在391名年龄≥18岁的马来西亚人中进行。通过谷歌表单分发的一份经过验证的在线自填问卷,用于评估对使用伊维菌素治疗COVID-19的知识、态度及使用情况。通过描述性分析评估受访者的社会人口学特征以及对伊维菌素使用的知识、态度和使用情况。采用卡方检验来确定变量之间的关联。

结果

受访者对伊维菌素使用的知识和态度水平中等,而伊维菌素的使用率为3.58%。受访者的性别(P=0.014)、年龄(P=0.012)和月收入(P=0.049)与他们的知识水平显著相关。受访者的性别(P=0.04)与他们的态度水平显著相关。相反,没有社会人口学特征与将伊维菌素用作COVID-19治疗的使用率显著相关。

结论

大多数马来西亚人对使用伊维菌素治疗COVID-19的知识和态度水平中等,实际使用率较低。

相似文献

3
Communicating COVID-19 Vaccine Safety: Knowledge and Attitude Among Residents of South East, Nigeria.
Infect Drug Resist. 2021 Sep 16;14:3785-3794. doi: 10.2147/IDR.S329183. eCollection 2021.
4
6
Knowledge, attitude, and practice among healthcare workers towards COVID-19 outbreak in Nigeria.
Heliyon. 2020 Nov;6(11):e05557. doi: 10.1016/j.heliyon.2020.e05557. Epub 2020 Nov 18.
7
Are Malaysians Ready to Resume the New Norm? Findings From a Nationwide Study.
Front Public Health. 2022 Jun 3;10:823047. doi: 10.3389/fpubh.2022.823047. eCollection 2022.
8
Knowledge, attitude and practices towards COVID-19 among higher education students in India: a cross sectional study.
Z Gesundh Wiss. 2022;30(7):1661-1673. doi: 10.1007/s10389-021-01561-7. Epub 2021 May 13.
9
Practice and Attitude Towards COVID-19 Prevention and Divine Belief Among Residents in Ethiopia: Cross-Sectional Survey.
Risk Manag Healthc Policy. 2021 Mar 10;14:987-995. doi: 10.2147/RMHP.S297846. eCollection 2021.
10
Prevalence of Ivermectin use to prevent COVID-19 during the pandemic in Mato Grosso: cross-sectional home-based study.
Rev Bras Epidemiol. 2023 May 8;26:e230026. doi: 10.1590/1980-549720230026. eCollection 2023.

引用本文的文献

本文引用的文献

2
Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.
BMJ Evid Based Med. 2022 Jun;27(3):156-158. doi: 10.1136/bmjebm-2021-111678. Epub 2021 Apr 22.
3
Clinical characteristics and risk factors for severe COVID-19 infections in Malaysia: A nationwide observational study.
Lancet Reg Health West Pac. 2020 Nov;4:100055. doi: 10.1016/j.lanwpc.2020.100055. Epub 2020 Nov 17.
4
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
5
Knowledge, Attitude and Practice Towards COVID-19 Among Chronic Disease Patients at Addis Zemen Hospital, Northwest Ethiopia.
Infect Drug Resist. 2020 Jun 24;13:1949-1960. doi: 10.2147/IDR.S258736. eCollection 2020.
6
Potential use of hydroxychloroquine, ivermectin and azithromycin drugs in fighting COVID-19: trends, scope and relevance.
New Microbes New Infect. 2020 Apr 22;35:100684. doi: 10.1016/j.nmni.2020.100684. eCollection 2020 May.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验